Fezolinetant and Hot Flashes: How Non-Hormonal Menopause Drugs Work
Hot flashes are often described as a consequence of “low estrogen.” That is only part of the story.
The menopause transition also changes the brain circuits responsible for temperature regulation. Fezolinetant targets one of those pathways directly, providing a treatment for hot flashes and night sweats without supplying estrogen or another hormone.
In the United States, fezolinetant is FDA-approved for moderate to severe vasomotor symptoms caused by menopause. It is a neurokinin 3 (NK3) receptor antagonist and works differently from menopausal hormone therapy. Clinical trials show that it can reduce the frequency and severity of hot flashes, but it requires liver-function monitoring because rare serious liver injury has been reported. (U.S. Food and Drug Administration)
Why Do Hot Flashes Happen?
Hot flashes and night sweats are collectively known as vasomotor symptoms.
They are linked to changes in the brain’s thermoregulatory system during the menopause transition. As estrogen levels change, signalling involving neurokinin B becomes disrupted within brain pathways involved in temperature control.
This effectively narrows the body’s thermoneutral zone—the temperature range within which the body does not need to actively cool or warm itself.
A relatively small change in core temperature can then trigger a disproportionate response: sudden heat, flushing, sweating and sometimes a subsequent chill.
This helps explain why a hot flash can appear to come from nowhere, including while sitting still or sleeping.
How Does Fezolinetant Work?
Fezolinetant does not replace estrogen.
It blocks neurokinin 3 receptors, which are involved in the signalling pathway controlling body temperature.
By reducing neurokinin B activity at these receptors, fezolinetant helps restore balance within the brain’s temperature-control system. The FDA describes this mechanism as addressing the altered balance between estrogen and neurokinin B signalling that occurs with menopause. (U.S. Food and Drug Administration)
This makes fezolinetant fundamentally different from hormone therapy.
Menopausal hormone therapy acts through hormone receptors and can treat several estrogen-related menopausal symptoms. Fezolinetant targets the neurological pathway underlying vasomotor symptoms specifically.
It is therefore better understood as a targeted non-hormonal hot-flash treatment, not a non-hormonal version of HRT.
How Effective Is Fezolinetant?
Large phase 3 trials have shown clinically meaningful reductions in moderate to severe vasomotor symptoms.
In the SKYLIGHT 1 trial, women aged 40 to 65 experiencing an average of at least seven moderate to severe hot flashes each day were randomly assigned to placebo or fezolinetant.
At the US-approved 45 mg dose, fezolinetant produced significantly greater reductions in hot-flash frequency than placebo at both four and 12 weeks. Improvements were already evident after the first week and were maintained through the longer treatment period. (PubMed)
SKYLIGHT 2 produced similar findings, with significant reductions in both frequency and severity of vasomotor symptoms compared with placebo. (PubMed)
A later phase 3b trial specifically studied 453 women for whom hormone therapy was considered unsuitable because it was contraindicated, required caution, had previously been discontinued, or was something they chose not to use. Fezolinetant again reduced vasomotor symptoms compared with placebo. (PubMed)
These findings matter because non-hormonal treatment is not required only by women who medically cannot take hormones. Some women simply prefer another option.
How Quickly Can It Work?
Clinical trials detected improvement within the first week of treatment.
That does not mean every woman will experience the same response or that symptoms disappear completely.
Treatment trials measure average changes across groups. Individual responses can range from substantial improvement to limited benefit.
The useful question is therefore not whether fezolinetant “stops hot flashes,” but whether it reduces their frequency or severity enough to meaningfully improve daily life or sleep.
Who Might Consider a Non-Hormonal Treatment?
There are several reasons a woman experiencing moderate to severe vasomotor symptoms might discuss a non-hormonal prescription treatment with her healthcare professional.
Some women have medical circumstances that make systemic menopausal hormone therapy inappropriate or require more careful risk assessment.
Others experience side effects with hormone therapy, do not obtain adequate symptom relief, or simply do not want to use hormones.
Fezolinetant expands the available choices because it treats vasomotor symptoms through a different biological pathway.
That does not make it inherently safer or more appropriate than hormone therapy for every woman. The two approaches have different benefits, risks, contraindications and treatment targets.
The decision should be individual.
Experiencing hot flashes, night sweats or other menopause symptoms? Join Sistapedia® free to explore trusted menopause information and discover verified healthcare professionals and Experts.
What Does Fezolinetant Not Treat?
This distinction is important.
Fezolinetant is FDA-approved specifically for moderate to severe vasomotor symptoms due to menopause. (U.S. Food and Drug Administration)
It should not be assumed to treat every symptom associated with menopause.
For example, genitourinary syndrome of menopause can involve vaginal dryness, irritation, painful sex and urinary symptoms related to estrogen deficiency in genital and urinary tissues. Those symptoms have their own treatment options.
Similarly, osteoporosis prevention and treatment involve a different clinical decision.
A woman experiencing several menopause-related problems may therefore need a treatment strategy addressing more than hot flashes alone.
This is one reason medication choice should begin with identifying which symptoms actually require treatment.
Why Is Liver Monitoring Required?
This is now one of the most important considerations for women taking fezolinetant in the United States.
In 2024, the FDA strengthened its safety warning after receiving a post-marketing report of serious liver injury in a patient taking fezolinetant. The agency subsequently added a Boxed Warning, its most prominent safety warning, for the risk of rare but serious liver injury. (U.S. Food and Drug Administration)
The FDA requires liver blood tests before treatment begins.
Under current US guidance, healthcare professionals should then perform hepatic laboratory testing monthly for the first three months, followed by testing at months six and nine. (U.S. Food and Drug Administration)
Fezolinetant should not be started if certain baseline liver-test results are already sufficiently elevated.
This monitoring requirement is not an optional extra. It is part of the medicine’s current safety framework.
What Symptoms of Liver Injury Should You Know?
The FDA advises patients taking fezolinetant to stop the medicine immediately and contact the prescribing healthcare professional if symptoms suggesting liver injury develop.
These can include unusual fatigue, nausea, vomiting, itching, light-colored stools, dark urine, yellowing of the skin or eyes, abdominal swelling or pain in the upper-right abdomen. (U.S. Food and Drug Administration)
These symptoms do not automatically mean liver injury has occurred.
But they should not be ignored or left until the next scheduled blood test.
The post-marketing case that prompted stronger FDA action developed symptoms within approximately 40 days of starting treatment, reinforcing why both laboratory monitoring and symptom awareness matter. (U.S. Food and Drug Administration)
What Are the Other Side Effects?
Like any prescription medicine, fezolinetant can cause adverse effects.
The FDA lists common adverse reactions including abdominal pain, diarrhea, insomnia and back pain. (U.S. Food and Drug Administration)
Clinical trials provide broader safety information. A pooled analysis of three phase 3 studies included more than 3,000 participants exposed to placebo or fezolinetant and evaluated treatment-emergent adverse events and liver-test abnormalities over treatment periods extending to 52 weeks. (PubMed)
However, clinical trials cannot identify every rare adverse effect before a medicine reaches a much larger population.
That is why post-marketing surveillance matters. The liver warning is a clear example of safety information evolving after approval.
Fezolinetant Versus Hormone Therapy: Is One Better?
There is no universal winner.
Menopausal hormone therapy remains an important evidence-based treatment for appropriate women experiencing bothersome menopausal symptoms. Fezolinetant provides another mechanism for treating vasomotor symptoms without administering hormones.
The appropriate comparison depends on the individual woman.
Questions include which symptoms need treatment, medical history, contraindications, personal treatment preferences, medication interactions and willingness to undertake ongoing liver monitoring.
The presence of a non-hormonal option should not be interpreted as evidence that hormone therapy is inherently unsafe.
Likewise, being eligible for hormone therapy does not mean a woman must choose it.
The value of newer treatments is greater choice based on individual clinical circumstances.
When to Seek Medical Assessment
Hot flashes are common during perimenopause and menopause, but not every episode of unexplained sweating or flushing should automatically be attributed to menopause.
Seek medical assessment when symptoms are new, unusual, severe, accompanied by other unexplained symptoms, or the diagnosis is uncertain.
If you are considering fezolinetant, a healthcare professional needs to assess whether the medicine is appropriate and arrange required baseline liver testing.
If you are already taking it, follow the prescribed monitoring schedule and seek prompt medical advice for symptoms potentially suggesting liver injury.
Do not stop prescribed menopause treatment or switch therapies solely on the basis of general information online unless urgent medication safety instructions specifically tell you to stop.
A New Way to Think About Hot Flashes
Fezolinetant represents more than another menopause medication.
It reflects a more detailed understanding of why vasomotor symptoms happen.
Hot flashes are not simply the body noticing that estrogen has fallen. They involve altered signalling within neural circuits regulating temperature, and those circuits can now be targeted pharmacologically without replacing estrogen.
That creates a genuinely different treatment pathway.
But “non-hormonal” should never be mistaken for “risk-free.”
Fezolinetant can provide meaningful symptom reduction, while its current US prescribing framework also requires women and clinicians to take liver safety seriously.
The useful question is not whether hormonal or non-hormonal treatment is universally better.
It is which treatment best matches your symptoms, medical history, risk profile and preferences—and what monitoring that treatment requires.
FAQs
Is fezolinetant a hormone?
No. Fezolinetant is a non-hormonal neurokinin 3 receptor antagonist. It targets a brain signalling pathway involved in temperature regulation rather than supplying estrogen. (U.S. Food and Drug Administration)
What is fezolinetant approved to treat?
In the United States, it is FDA-approved to treat moderate to severe vasomotor symptoms—hot flashes and night sweats—caused by menopause. (U.S. Food and Drug Administration)
How quickly does fezolinetant work?
Phase 3 clinical trials found improvements in vasomotor symptoms within the first week, with benefits maintained during longer treatment. Individual responses vary. (PubMed)
Why do I need blood tests while taking fezolinetant?
Rare serious liver injury has been reported. The FDA requires liver testing before treatment, monthly for the first three months, and again at months six and nine. (U.S. Food and Drug Administration)
Is fezolinetant better than HRT?
Not universally. They work differently and have different benefits, risks and clinical uses. Treatment should be selected according to symptoms, medical history and individual preferences.
Continue on Sistapedia®
For Sistas: Join Sistapedia® free to explore trusted information across menopause and women’s reproductive health. Complete free Pink Tick identity verification to participate as a genuine identity-verified Sista and share your experience if you choose.
For healthcare professionals and Experts: Establish your professional presence and contribute evidence-informed education across Sistapedia®. Eligible Medical Doctors, Doctors of Osteopathic Medicine, General Practitioners, Registered Nurses, Healthcare Practitioners and Experts can apply for Crown Verification through the Verification tab in their profile.
Sources
U.S. Food and Drug Administration — FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. (U.S. Food and Drug Administration)
Lederman S, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The Lancet. 2023. (PubMed)
Schaudig K, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024. (PubMed)
Pooled phase 3 safety analysis of SKYLIGHT 1, SKYLIGHT 2 and SKYLIGHT 4. (PubMed)
Medical disclaimer: This article provides general educational information and does not replace personalised medical advice, diagnosis or treatment. Speak with an appropriately qualified healthcare professional about symptoms, medicines, tests or treatment decisions.
Google